Category
Nine vaccinated people caught the wrong Ebola species and all nine survived. Not proof — but an argument that the question should be tested rather than debated.
Professional societies issued their own respiratory-season vaccine guidance, developed independently of the federal advisory process. The clinical advice is unremarkable; the fact that they had to issue it is not.
Every flu vaccine on the market aims at one surface protein. GSK’s mRNA candidate adds a second — the one associated with reduced severity and transmission rather than with blocking infection.
Immune memory is supposed to belong to T and B cells. A lung cell that is neither turns out to sustain the local defences that stop flu at the airway — and adding its protein to a nasal vaccine worked.
The 2026–27 shots target XFG, which accounts for about 79% of US cases. The more consequential change is who is eligible — no longer everyone.
4,500 cases and 2,060 deaths in Ituri, spreading faster than any previous outbreak. WHO is proposing to randomise contacts individually rather than by ring — a change with real trade-offs.
Egg-grown flu vaccines force a strain guess months ahead. mRNA compresses that lead time — which is the actual argument, not the 27%.
Medigen already sells an EV71 vaccine in Taiwan and Vietnam. Broadening it to cover more enterovirus strains is the harder problem — and Charles River supplies the machinery for proving it.
A Zika vaccine that generates antibodies could make a later dengue infection worse. So the researchers deliberately engineered the antibody response out and protected with T cells instead.
Another large study, another 24% lower dementia rate among the vaccinated. The authors say plainly it cannot establish cause — and explain exactly why their adjustments did not close the gap.
Antibodies against Staph, RSV and a common respirovirus predicted how well people responded to COVID vaccination — not because they fight COVID, but because they reveal the immune system’s general capacity.
There has been no human Lyme vaccine for two decades — one was withdrawn in 2002 amid safety claims never substantiated. A 9,437-person Phase 3 now sits with the EMA.
Two vaccines, 12,717 participants, 38 months. Some real protective signals in specific groups — and no protection at all in underweight people, which is where TB concentrates.
A vaccine built individually for each patient from their own tumour’s mutations. The first randomised Phase 3 to test whether that works — and it did.